Non-Small Cell Lung Carcinoma | Squamous cell carcinoma | Adenocarcinoma | Carcinoma, Large Cell | Bronchioloalveolar Adenocarcinoma | Non-small cell carcinoma
Item
1. histological confirmation of non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma, large cell carcinoma, bronchoalveolar cell carcinoma, or non-small cell carcinoma nos) by either biopsy or cytology.
boolean
C0007131 (UMLS CUI [1])
C0007137 (UMLS CUI [2])
C0001418 (UMLS CUI [3])
C0206704 (UMLS CUI [4])
C0007120 (UMLS CUI [5])
C1266002 (UMLS CUI [6])
TNM clinical staging
Item
2. clinical ajcc stage iia (t1n1m0), iib (t2,n1m0, t3,n0,m0) or iiia (t1-3, n1-2,m0)/selected iiib. in all cases, patients may be included at the discretion of the treating radiation oncologist if it will be likely the disease can be encompassed by the stereotactic boost will be included.
boolean
C3258246 (UMLS CUI [1])
Hilar lymphadenopathy Size CT scan pre treatment | Mediastinal lymphadenopathy Size CT scan pre treatment | Hilar lymphadenopathy Size PET pre treatment | Mediastinal lymphadenopathy Size PET pre treatment | Hilar lymphadenopathy Size Mediastinoscopy pre treatment | Mediastinal lymphadenopathy Size Mediastinoscopy pre treatment
Item
3. patients with non-bulky (< 2.0-3.0 cm) hilar or mediastinal lymphadenopathy determined by pre-treatment ct scan, pet or mediastinoscopy
boolean
C0456973 (UMLS CUI [1,1])
C0456389 (UMLS CUI [1,2])
C0040405 (UMLS CUI [1,3])
C2709094 (UMLS CUI [1,4])
C0520743 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
C0040405 (UMLS CUI [2,3])
C2709094 (UMLS CUI [2,4])
C0456973 (UMLS CUI [3,1])
C0456389 (UMLS CUI [3,2])
C0032743 (UMLS CUI [3,3])
C2709094 (UMLS CUI [3,4])
C0520743 (UMLS CUI [4,1])
C0456389 (UMLS CUI [4,2])
C0032743 (UMLS CUI [4,3])
C2709094 (UMLS CUI [4,4])
C0456973 (UMLS CUI [5,1])
C0456389 (UMLS CUI [5,2])
C0025065 (UMLS CUI [5,3])
C2709094 (UMLS CUI [5,4])
C0520743 (UMLS CUI [6,1])
C0456389 (UMLS CUI [6,2])
C0025065 (UMLS CUI [6,3])
C2709094 (UMLS CUI [6,4])
Chemoradiotherapy Standard Course Completed
Item
4. must have completed a standard course of chemoradiation in accordance with nccn guidelines
boolean
C0436307 (UMLS CUI [1,1])
C1442989 (UMLS CUI [1,2])
C0750729 (UMLS CUI [1,3])
C0205197 (UMLS CUI [1,4])
Status post Chemoradiotherapy | Status post CT | Status post PET-CT | Residual Tumor Volume Limited | Site Tumor Mass Primary | Tumor Mass Size Post Chemoradiotherapy
Item
5. one month following definitive chemoradiation, ct or pet-ct revealing limited volume residual disease within the site of primary tumour mass (post-chemo/rt mass </= 7.0 cm). patients with a cr and no obvious target are not eligible.
boolean
C0231290 (UMLS CUI [1,1])
C0436307 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C0231290 (UMLS CUI [3,1])
C1699633 (UMLS CUI [3,2])
C0543478 (UMLS CUI [4,1])
C0449468 (UMLS CUI [4,2])
C0439801 (UMLS CUI [4,3])
C1515974 (UMLS CUI [5,1])
C3273930 (UMLS CUI [5,2])
C0205225 (UMLS CUI [5,3])
C3273930 (UMLS CUI [6,1])
C0456389 (UMLS CUI [6,2])
C0687676 (UMLS CUI [6,3])
C0436307 (UMLS CUI [6,4])
Patient Appropriate Frame-based stereotactic device
Item
6. must be able to fit into the elekta stereotactic body frame
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0582732 (UMLS CUI [1,3])
Age
Item
7. patients must be ≥ 18 years of age.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
8. the patient's ecog performance status must be 0-2.
boolean
C1520224 (UMLS CUI [1])
Childbearing Potential Contraceptive methods | Gender Contraceptive methods
Item
9. women of childbearing potential and male participants must use an effective contraceptive method.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
Informed Consent
Item
10. patients must sign a study-specific consent form.
boolean
C0021430 (UMLS CUI [1])
Cancer Other | Malignant Neoplasm Previous | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in situ of uterine cervix Treated | Exception Cancer Other Disease Free of
Item
1. any other active cancer or no prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer from which the patient has been disease-free for 5 years.
boolean
C1707251 (UMLS CUI [1])
C0006826 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0851140 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C1707251 (UMLS CUI [6,2])
C0012634 (UMLS CUI [6,3])
C0332296 (UMLS CUI [6,4])
Systemic disease | First line treatment Recovery Lacking | Carcinoma of lung Progressing
Item
2. patients with other systemic illness, or have not recovered adequately from their primary treatment or who have evidence of progression of their lung cancer prior to therapy that, in the investigators opinions, would preclude their inclusion
boolean
C0442893 (UMLS CUI [1])
C1708063 (UMLS CUI [2,1])
C2004454 (UMLS CUI [2,2])
C0332268 (UMLS CUI [2,3])
C0684249 (UMLS CUI [3,1])
C0205329 (UMLS CUI [3,2])
Antineoplastic Agents Planned | Exception Disease Progression | Exception Diphosphonates Hypercalcemia
Item
3. plans for the patient to receive other concomitant antineoplastic therapy while on this protocol, except at disease progression. patients may be allowed to use bisphosphonates for hypercalcemia.
boolean
C0003392 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0242656 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0012544 (UMLS CUI [3,2])
C0020437 (UMLS CUI [3,3])
Pregnancy | Breast Feeding
Item
4. pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])